Karyopharm’s Selinexor receive FDA Fast Track designation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Karyopharm Therapeutics Inc. received the FDA Fast Track designation for an oral Selective Inhibitor of Nuclear Export compound selinexor for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login